FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Timothy Clay

Research Profile

Chemicals & Drugs

Anatomy

Disorders

Procedures

Living Beings

Physiology

Cell Proliferation

Co-author Network

Publications

TOP 3
Takuya Osada; Jonathan Smith; Xiao Yi Yang; Whitney Lewis; Michael A Morse; Donna Niedzwiecki; Peter Berglund; Bruce Burnett; Timothy M Clay; Gayathri R Devi; Amy C Hobeika; Bolyn Hubby; H Kim Lyerly
Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.
Ping Zhang; Timothy M Clay; Alex R Kemper; Xiaoyan Luo; Takuya Osada; Ramona Rodriguiz; Baodong Sun; Xiao Yi Yang; Dwight D Koeberl
Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.
Nicholas C D'Amato; Alyssa Dawson; Jeff Delrow; Krzysztof Mrózek; Takuya Osada; Julie Hanson Ostrander; Robin E Bachelder; Katie Bell; Alexander D Borowsky; Michelle L Bowie; Robert Cardiff; Timothy M Clay; Karl Simin; Christopher Sistrunk; Lisa D Yee; Lawrence J T Young; Victoria L Seewaldt
Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Timothy Clay (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Takuya Osada; Jonathan Smith; Xiao Yi Yang; Whitney Lewis; Michael A Morse; Donna Niedzwiecki; Peter Berglund; Bruce Burnett; Timothy M Clay; Gayathri R Devi; Amy C Hobeika; Bolyn Hubby; H Kim Lyerly
Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.
Cancer immunology, immunotherapy : CII 2012;61(11):1941-51.
2012: Ping Zhang; Timothy M Clay; Alex R Kemper; Xiaoyan Luo; Takuya Osada; Ramona Rodriguiz; Baodong Sun; Xiao Yi Yang; Dwight D Koeberl
Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.
Human gene therapy 2012;23(5):460-72.
2012: Nicholas C D'Amato; Alyssa Dawson; Jeff Delrow; Krzysztof Mrózek; Takuya Osada; Julie Hanson Ostrander; Robin E Bachelder; Katie Bell; Alexander D Borowsky; Michelle L Bowie; Robert Cardiff; Timothy M Clay; Karl Simin; Christopher Sistrunk; Lisa D Yee; Lawrence J T Young; Victoria L Seewaldt
Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system.
PloS one 2012;7(9):e45684.
2012: Xiu-Rong Ren; Neil Spector; Jiangbo Wang; Junping Wei; Wenle Xia; Larry S Barak; Kimberly Blackwell; Timothy M Clay; Erika Hamilton; Amy C Hobeika; Gangjun Lei; Jiuyi Lu; H Kim Lyerly; Michael A Morse; Takuya Osada; Wei Chen
Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.
Breast cancer research : BCR 2012;14(3):R89.
2012: Erika Hamilton; Amy C Hobeika; Frederic Lehmann; H Kim Lyerly; Takuya Osada; Xiu-Rong Ren; Neil Spector; Junping Wei; Kimberly Blackwell; Gloria Broadwater; Henry Castro; Wei Chen; Timothy M Clay; Michael A Morse
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].
Journal of translational medicine 2012;10():28.
2011: Zachary Conrad Hartman; Amy C Hobeika; Jean-Bernard Le Pecq; Gangjun Lei; Timothy M Clay; Alain Delcayre; Oliver K Glass; Hongtao Guo; Michael A Morse; Takuya Osada; Junping Wei; Xiao-Yi Yang; Herbert K Lyerly
Increasing vaccine potency through exosome antigen targeting.
Vaccine 2011;29(50):9361-7.
2011: Erika Hamilton; Timothy M Clay; Kimberly L Blackwell
New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.
Cancer investigation 2011;29(8):533-41.
2011: Wenle Xia; Xiao-Yi Yang; Sumin Zhao; Rongrong Zong; Julia D Wulfkuhle; Sarah S Bacus; Kimberly L Blackwell; Timothy M Clay; Zachary Conrad Hartman; Jia He; Leihua Liu; Zuguo Liu; H Kim Lyerly; Yubin Mao; Takuya Osada; Emanuel F Petricoin; Neil L Spector
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.
Molecular cancer therapeutics 2011;10(8):1367-74.
2011: Zachary Conrad Hartman; Gangjun Lei; Timothy M Clay; Sandeep S Dave; Oliver Glass; Michael A Morse; Takuya Osada; Xiao-Yi Yang; H Kim Lyerly
HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis.
Cancer research 2011;71(13):4380-91.
2011: Takuya Osada; Ivan Spasojevic; Jeffrey B Vandeusen; Xiao Yi Yang; Minyong Chen; Wei Chen; Bryan M Clary; Timothy M Clay; David Hsu; Michael A Morse; H Kim Lyerly
Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.
Cancer research 2011;71(12):4172-82.
2011: Timothy M Clay; Takuya Osada; Zachary Conrad Hartman; Amy C Hobeika; Gayathri Devi; Michael A Morse; H Kim Lyerly
Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.
Immunologic research 2011;49(1-3):235-47.
2011: Amy C Hobeika; Michael A Morse; Takuya Osada; Sharon Peplinski; H Kim Lyerly; Timothy M Clay
Depletion of human regulatory T cells.
Methods in molecular biology (Clifton, N.J.) 2011;707():219-31.
2010: Zachary Conrad Hartman; Takuya Osada; Oliver Glass; Xiao Y Yang; Gang-Jun Lei; H Kim Lyerly; Timothy M Clay
Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity.
Cancer research 2010;70(18):7209-20.
2010: Michael A Morse; Junping Wei; Zachary Hartman; Wenle Xia; Xiu-Rong Ren; Gangjun Lei; William T Barry; Takuya Osada; Amy C Hobeika; Sharon Peplinski; Haixiang Jiang; Gayathri R Devi; Wei Chen; Neil Spector; Andrea Amalfitano; H Kim Lyerly; Timothy M Clay
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
International journal of cancer. Journal international du cancer 2010;126(12):2893-903.
2010: Zachary Conrad Hartman; Junping Wei; Takuya Osada; Oliver Glass; Gangjun Lei; Xiao-Yi Yang; Sharon Peplinski; Dong-Wan Kim; Wenle Xia; Neil Spector; Jeffrey Marks; William Barry; Amy Hobeika; Gayathri Devi; Andrea Amalfitano; Michael A Morse; H Kim Lyerly; Timothy M Clay
An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1466-77.
2010: Baodong Sun; Michael D Kulis; Sarah P Young; Amy C Hobeika; Songtao Li; Andrew Bird; Haoyue Zhang; Yifan Li; Timothy M Clay; Wesley Burks; Priya S Kishnani; Dwight D Koeberl
Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease.
Molecular therapy : the journal of the American Society of Gene Therapy 2010;18(2):353-60.
2009: T Osada; X Y Yang; Zachary Conrad Hartman; O Glass; B L Hodges; D Niedzwiecki; M A Morse; H Kim Lyerly; Andrea Amalfitano; Timothy M Clay
Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.
Cancer gene therapy 2009;16(9):673-82.
2009: Yanal M Murad; Timothy M Clay
CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2009;23(6):361-75.
2008: Michael A Morse; Amy C Hobeika; Takuya Osada; Delila Serra; Donna Niedzwiecki; H Kim Lyerly; Timothy M Clay
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.
Blood 2008;112(3):610-8.
2008: Takuya Osada; Gabriel Chong; Robert Tansik; Timothy Hong; Neil Spector; Rakesh Kumar; Herbert I Hurwitz; Inderjit Dev; Andrew Nixon; H Kim Lyerly; Timothy M Clay; Michael A Morse
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
Cancer immunology, immunotherapy : CII 2008;57(8):1115-24.
2008: Zachary Conrad Hartman; Daniel M Appledorn; Delila Serra; Oliver Glass; Todd B Mendelson; Timothy M Clay; Andrea Amalfitano
Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.
Virology 2008;374(2):453-67.
2008: Amy C Hobeika; Takuya Osada; D Serra; S Peplinski; K Hanson; Y Tanaka; Donna Niedzwiecki; Nelson J Chao; D Rizzieri; Hk Lyerly; Timothy M Clay; Ma Morse
Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.
Cytotherapy 2008;10(3):289-302.
2008: Holden T Maecker; Jeffrey Hassler; Janice K Payne; Amanda Summers; Karrie Comatas; Manar Ghanayem; Michael A Morse; Timothy M Clay; H Kim Lyerly; Sonny Bhatia; Smita A Ghanekar; Vernon C Maino; Corazon Delarosa; Mary L Disis
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.
BMC immunology 2008;9():9.
2008: Katherine M Aird; Xiuyun Ding; Aris Baras; Junping Wei; Michael A Morse; Timothy M Clay; H Kim Lyerly; Gayathri Devi
Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.
Molecular cancer therapeutics 2008;7(1):38-47.
2007: Michael Morse; Lee Langer; Alexander Starodub; Amy C Hobeika; Timothy M Clay; H Kim Lyerly
Current immunotherapeutic strategies in colon cancer.
Surgical oncology clinics of North America 2007;16(4):873-900, x.
2007: Yanal Murad; Timothy M Clay; H Kim Lyerly; Michael A Morse
CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.
Expert opinion on biological therapy 2007;7(8):1257-66.
2007: Lee F Langer; Timothy M Clay; Michael A Morse
Update on anti-CTLA-4 antibodies in clinical trials.
Expert opinion on biological therapy 2007;7(8):1245-56.
2007: Benjamin F Johnson; Timothy M Clay; Amy C Hobeika; H Kim Lyerly; Michael A Morse
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.
Expert opinion on biological therapy 2007;7(4):449-60.
2007: Yalonda Hutchings; Takuya Osada; Christopher Y Woo; Timothy M Clay; H Kim Lyerly; Michael A Morse
Immunotherapeutic targeting of Wilms' tumor protein.
Current opinion in molecular therapeutics 2007;9(1):62-9.
2007: Zachary Conrad Hartman; Anne Kiang; Ruth S Everett; Delila Serra; Xiao Y Yang; Timothy M Clay; Andrea Amalfitano
Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo.
Journal of virology 2007;81(4):1796-812.
2007: Michael A Morse; Amy C Hobeika; Takuya Osada; Donna Niedzwiecki; Paul Kelly Marcom; Kimberly L Blackwell; Carey Anders; Gayathri Devi; H Kim Lyerly; Timothy M Clay
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.
Journal of translational medicine 2007;5():42.
2007: Zhenlin Hu; Xiao Yi Yang; Yunbo Liu; georgy sankin; Eric C Pua; Michael A Morse; H Kim Lyerly; Timothy M Clay; Pei Zhong
Investigation of HIFU-induced anti-tumor immunity in a murine tumor model.
Journal of translational medicine 2007;5():34.
2007: Paul J Mosca; H Kim Lyerly; Timothy M Clay; Michael A Morse; H Kim Lyerly
Dendritic cell vaccines.
Frontiers in bioscience : a journal and virtual library 2007;12():4050-60.
2006: Christopher Y Woo; Takuya Osada; Timothy M Clay; H Kim Lyerly; Michael A Morse
Recent clinical progress in virus-based therapies for cancer.
Expert opinion on biological therapy 2006;6(11):1123-34.
2006: Takuya Osada; Timothy M Clay; Christopher Y Woo; Michael A Morse; H Kim Lyerly
Dendritic cell-based immunotherapy.
International reviews of immunology 2006;25(5-6):377-413.
2006: Takuya Osada; Timothy M Clay; Amy C Hobeika; H Kim Lyerly; Michael A Morse
NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.
Cancer immunology, immunotherapy : CII 2006;55(9):1122-31.
2006: Christopher Y Woo; Timothy M Clay; H Kim Lyerly; Michael A Morse; Takuya Osada
Role of natural killer cell function in dendritic cell-based vaccines.
Expert review of vaccines 2006;5(1):55-65.
2006: Mary L Disis; Corazon dela Rosa; Vivian Goodell; Ling-Yu Kuan; Jennie C C Chang; Kristina Kuus-Reichel; Timothy M Clay; H Kim Lyerly; Sonny Bhatia; Smita A Ghanekar; Vernon C Maino; Holden T Maecker
Maximizing the retention of antigen specific lymphocyte function after cryopreservation.
Journal of immunological methods 2006;308(1-2):13-8.
2005: Luis M Franco; Baodong Sun; Xiaoyi Yang; Andrew Bird; Haoyue Zhang; Ayn Schneider; Talmage Brown; Sarah P Young; Timothy M Clay; Andrea Amalfitano; Yuan-Tsong Chen; Dwight D Koeberl
Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.
Molecular therapy : the journal of the American Society of Gene Therapy 2005;12(5):876-84.
2005: Zhenlin Hu; Xiao Yi Yang; Yunbo Liu; Michael A Morse; H Kim Lyerly; Timothy M Clay; Pei Zhong
Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs.
Biochemical and biophysical research communications 2005;335(1):124-31.
2005: Takuya Osada; Michael A Morse; H Kim Lyerly; Timothy M Clay
Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.
International immunology 2005;17(9):1143-55.
2005: Stephen Y (Steve) Chui; Timothy M Clay; H Kim Lyerly; Michael A Morse
The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005;14(8):1883-9.
2005: Michael A Morse; Timothy M Clay; Amy C Hobeika; Takuya Osada; Shubi Khan; Stephen Y (Steve) Chui; Donna Niedzwiecki; Dennis Panicali; Jeffrey Schlom; H Kim Lyerly
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(8):3017-24.
2005: Michael A Morse; Stephen Y (Steve) Chui; Amy C Hobeika; H Kim Lyerly; Timothy M Clay
Recent developments in therapeutic cancer vaccines.
Nature clinical practice. Oncology 2005;2(2):108-13.
2005: Paul J Mosca; Timothy M Clay; Michael A Morse; H Kim Lyerly
Immune monitoring.
Cancer treatment and research 2005;123():369-88.
2005: Michael I Nishimura; Jeffrey J Roszkowski; Tamson V Moore; Natasha Brasic; Mark D McKee; Timothy M Clay
Antigen recognition and T-cell biology.
Cancer treatment and research 2005;123():37-59.
2005: Holden T Maecker; James Moon; Sonny Bhatia; Smita A Ghanekar; Vernon C Maino; Janice K Payne; Kristine Kuus-Reichel; Jennie C Chang; Amanda Summers; Timothy M Clay; Michael A Morse; H Kim Lyerly; Corazon DeLaRosa; Donna Pauler Ankerst; Mary L Disis
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT.
BMC immunology 2005;6():17.
2005: Amy C Hobeika; Michael A Morse; Takuya Osada; Manar Ghanayem; Donna Niedzwiecki; Robert Barrier; H Kim Lyerly; Timothy M Clay
Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(1):63-72.
2004: Michael A Morse; H Kim Lyerly; Timothy M Clay; Omar I Abdel-Wahab; Stephen Y (Steve) Chui; Jennifer Garst; Jared A Gollob; Peter M Grossi; Matthew F Kalady; Paul J Mosca; Mark W Onaitis; John H Sampson; Hilliard F Seigler; Eric M Toloza; Douglas Tyler; Zhen Su; Yiping Yang
Immunotherapy of surgical malignancies.
Current problems in surgery 2004;41(1):15-132.
2003: Michael A Morse; Timothy M Clay; Kirsten Colling; H Kim Lyerly
Preparation of peptide-loaded dendritic cells for cancer immunotherapy.
Molecular biotechnology 2003;25(1):95-9.
2003: Michael A Morse; Smita K Nair; Paul J Mosca; Amy C Hobeika; Timothy M Clay; Yuping Deng; David Boczkowski; Alan D Proia; Donna Neidzwiecki; Pierre-Alain Clavien; Herbert I Hurwitz; Jeffrey Schlom; Eli Gilboa; H Kim Lyerly
Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA.
Cancer investigation 2003;21(3):341-9.
2003: Paul J Mosca; Timothy M Clay; H Kim Lyerly; Michael A Morse
Current status of dendritic cell immunotherapy of malignancies.
International reviews of immunology 2003;22(3-4):255-81.
2003: Barbara L F Kaplan; David C Yu; Timothy M Clay; Michael I Nishimura
Redirecting T lymphocyte specificity using T cell receptor genes.
International reviews of immunology 2003;22(3-4):229-53.
2003: Paul J Mosca; H Kim Lyerly; C Denise Ching; Amy C Hobeika; Timothy M Clay; Michael A Morse
Proteomics for monitoring immune responses to cancer vaccines.
Current opinion in molecular therapeutics 2003;5(1):39-43.
2003: Michael A Morse; Timothy M Clay; Kirsten Colling; Amy C Hobeika; Kenneth H Grabstein; Martin A Cheever; H Kim Lyerly
HER2 dendritic cell vaccines.
Clinical breast cancer 2003;3 Suppl 4():S164-72.
2003: Michael A Morse; Stephen Y (Steve) Chui; Timothy M Clay; H Kim Lyerly
Recent areas of development for dendritic cell vaccines.
Cancer chemotherapy and biological response modifiers 2003;21():339-50.
2003: Timothy M Clay; Michael I Nishimura
Retroviral transfer of T-cell receptor genes into human peripheral blood lymphocytes.
Methods in molecular biology (Clifton, N.J.) 2003;215():227-34.
2002: Michael A Morse; Timothy M Clay; Paul J Mosca; H Kim Lyerly
Immunoregulatory T cells in cancer immunotherapy.
Expert opinion on biological therapy 2002;2(8):827-34.
2002: Paul J Mosca; Amy C Hobeika; Kirsten Colling; Timothy M Clay; Elaine K Thomas; Dania Caron; H Kim Lyerly; Michael A Morse
Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand.
Journal of leukocyte biology 2002;72(3):546-53.
2002: Michael A Morse; David A Rizzieri; Timothy T Stenzel; Amy C Hobeika; James J Vredenburgh; Nelson J Chao; Timothy M Clay; Paul J Mosca; H Kim Lyerly
Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants.
Journal of hematotherapy & stem cell research 2002;11(4):659-68.
2002: Timothy M Clay; Michael Morse; H Kim Lyerly
Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes.
Expert opinion on biological therapy 2002;2(4):353-60.
2002: Michael A Morse; Timothy M Clay; H Kim Lyerly
Current status of adoptive immunotherapy of malignancies.
Expert opinion on biological therapy 2002;2(3):237-47.
2002: Michael A Morse; Timothy M Clay; H Kim Lyerly
CEA loaded dendritic cell vaccines.
Cancer chemotherapy and biological response modifiers 2002;20():385-90.
2002: Michael A Morse; Smita K Nair; David Boczkowski; Douglas Tyler; Herbert I Hurwitz; Alan D Proia; Timothy M Clay; Jeffrey Schlom; Eli Gilboa; H Kim Lyerly
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.
International journal of gastrointestinal cancer 2002;32(1):1-6.
2002: Michael A Morse; Paul J Mosca; Timothy M Clay; H Kim Lyerly
Dendritic cell maturation in active immunotherapy strategies.
Expert opinion on biological therapy 2002;2(1):35-43.
2001: Timothy M Clay; Amy C Hobeika; Paul J Mosca; H Kim Lyerly; Michael A Morse
Assays for monitoring cellular immune responses to active immunotherapy of cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1127-35.
2001: Michael A Morse; Timothy M Clay; Amy C Hobeika; Paul J Mosca; H Kim Lyerly
Surrogate markers of response to cancer immunotherapy.
Expert opinion on biological therapy 2001;1(2):153-8.
2001: Paul J Mosca; Amy C Hobeika; Timothy M Clay; Michael A Morse; H Kim Lyerly
Direct detection of cellular immune responses to cancer vaccines.
Surgery 2001;129(3):248-54.
2001: Michael A Morse; Timothy M Clay; Amy C Hobeika; Paul J Mosca; H Kim Lyerly
Monitoring cellular immune responses to cancer immunotherapy.
Current opinion in molecular therapeutics 2001;3(1):45-52.
2001: Amy C Hobeika; Timothy M Clay; Paul J Mosca; H Kim Lyerly; Michael A Morse
Quantitating therapeutically relevant T-cell responses to cancer vaccines.
Critical reviews in immunology 2001;21(1-3):287-97.
2000: Michael A Morse; Smita Nair; M Fernandez-Casal; Y Deng; M St Peter; R Williams; Amy C Hobeika; Paul J Mosca; Timothy M Clay; R Ian Cumming; E Fisher; Pierre-Alain Clavien; Alan D Proia; Donna Niedzwiecki; D Caron; H Kim Lyerly
Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(23):3883-93.
2000: Paul J Mosca; Amy C Hobeika; Timothy M Clay; Smita K Nair; E K Thomas; Michael A Morse; H Kim Lyerly
A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment.
Blood 2000;96(10):3499-504.
2000: MD McKee; Timothy M Clay; R A Diamond; STEVEN ROSENBERG; Michael I Nishimura
Quantitation of T-cell receptor frequencies by competitive polymerase chain reaction: dynamics of T-cell clonotype frequencies in an expanding tumor-infiltrating lymphocyte culture.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(4):419-29.
1999: Timothy M Clay; Mary Custer; J Sachs; Patrick Hwu; STEVEN ROSENBERG; Michael I Nishimura
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(1):507-13.
1999: MD McKee; Timothy M Clay; STEVEN ROSENBERG; Michael I Nishimura
Quantitation of T-cell receptor frequencies by competitive PCR: generation and evaluation of novel TCR subfamily and clone specific competitors.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(2):93-102.
1999: Timothy M Clay; Mary Custer; MD McKee; Maria R Parkhurst; Paul F Robbins; Kimberly F Kerstann; John R Wunderlich; STEVEN ROSENBERG; Michael I Nishimura
Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(3):1749-55.
1999: Timothy M Clay; Mary Custer; Paul J Spiess; Michael I Nishimura
Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.
Pathology oncology research : POR 1999;5(1):3-15.
1998: Michael I Nishimura; Mary Custer; Susan L Schwarz; Linda L Parker; Arnold Mixon; Timothy M Clay; J R Yannelli; STEVEN ROSENBERG
T cell-receptor V gene use by CD4+ melanoma-reactive clonal and oligoclonal T-cell lines.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(5):352-62.
1996: DJ Loftus; Chiara Castelli; Timothy M Clay; Paola Squarcina; Francesco M Marincola; Michael I Nishimura; Giorgio Parmiani; Ettore Appella; Licia Rivoltini
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).
The Journal of experimental medicine 1996;184(2):647-57.